To address this uncertainty, we assessed the association of hs-cTnT levels with recurrent CVD events in the STROKE-CARD trial, a pragmatic trial of a disease management program, which included patients with a broad spectrum of disease severity spanning from moderate-risk TIA to major ischemic stroke. Here, TNNT2 is linked to transient ischemic attack.